Micronoma develops a liquid biopsy that decrypts signals from the tumor-related microbiome to detect cancer at an early stage. The company leverages its Oncobiota™ platform to analyze microbiome-derived signals from all genomes. It is led by CEO Sandrine Miller-Montgomery and is based in San Diego, California. Micronoma recently closed a $3.5M convertible debt financing and has raised a total of $6.5M since its first seed round six months earlier. The company intends to use the funds to complete a validation study on lung cancer prediction, set up CLIA operations, and establish its go-to-market strategy. It also plans to initiate work on a second cancer target. Micronoma develops a minimally invasive, microbiome-based diagnostic approach that uses microbial nucleic acids in human blood and tissues to detect distinct cancer types. The company has exclusively licensed the original IP on microbial-based cancer diagnostics and therapeutics from UC San Diego. Micronoma's method can query multiple cancer types from a single small blood sample, though the company will initially focus on early detection of lung cancer. Micronoma plans to use its recent funding to advance microbiome research, progress development work, and establish a CLIA-certified laboratory. The technology was created by co-founders Greg Poore and Dr. Rob Knight; Sandrine Miller-Montgomery serves as CEO. The company was incorporated in June 2019 and is based in San Diego, CA.

Total raised

$7M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Feb 2021